CD4 and neoplasm: Innovations such as ligand-functionalized nanoparticles, pH-responsive carriers, and biomimetic nanocarriers further enhance the ability to selectively modulate immune responses within the tumour microenvironment, thereby potentiating CD4+ T-cell activation and function (Niculescu and Grumezescu, 2022; Gowd et al., 2022).